<a href="https://laohu8.com/S/MTNB">Matinas BioPharma</a> Extends CEO Retention Bonus and Updates Change in Control Terms
Matinas BioPharma Holdings Inc. has amended the employment agreement with Chief Executive Officer Jerome D. Jabbour. Under the new terms, the deadline for a Change in Control event that would trigger Jabbour's retention bonus has been extended from March 31, 2026, to June 30, 2026. The retention bonus will be the greater of his target annual bonus for the year in which the Change in Control occurs or $299,000. Two-thirds of this bonus will be paid upon execution of a definitive agreement for a Change in Control, with the remaining one-third paid immediately prior to the closing of the transaction, contingent on Jabbour's continued employment. Additionally, Jabbour is guaranteed an annual bonus for 2025 equal to at least his target amount, to be paid no later than February 1, 2026, provided he remains with the company. The agreement also updates definitions related to "Change in Control," "Cause," and "Good Reason."
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Matinas BioPharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-027529), on December 12, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。